<table id="table8" width="75%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 8: Selected Drug Interactions in Adults</caption>
<col align="left" valign="top" width="30%"></col>
<col align="center" valign="top" width="20%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Concomitant Drug Class:<br/>Drug Name</th>
<th stylecode="Rrule">Effect on Concentration of Raltegravir</th>
<th align="center" stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Metal-Containing Antacids</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">aluminum and/or magnesium-containing antacids</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">Coadministration or staggered administration of aluminum and/or magnesium hydroxide-containing antacids and ISENTRESS is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">rifampin</td>
<td stylecode="Rrule">↓</td>
<td stylecode="Rrule">The recommended dosage of ISENTRESS is 800 mg twice daily during coadministration with rifampin. There are no data to guide co-administration of ISENTRESS with rifampin in patients below 18 years of age <content stylecode="italics">[see <linkhtml href="#S2.1">Dosage and Administration (2.1)</linkhtml>].</content>
</td>
</tr>
</tbody>
</table>